Press "Enter" to skip to content

The New York Times reports: After weeks of cutting deals and stroking drug makers.

This content is certainly republished with kind permission from our friends at The Kaiser Family Foundation. You can view the complete Kaiser Daily Health Policy Record, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, discussions and debates. The Daily Health Policy Report is published for Kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Table Kaiser and Company Family members Foundation. All rights reserved.. Administration officials court essential lawmakers on health care Administration officials are courting key stakeholders on healthcare increasingly. The New York Times reports: After weeks of cutting deals and stroking drug makers, hospitals and doctors, the president’s aides are laying the groundwork for your final round of Congressional arm-twisting.PLX4302 differs because it attacks the genetic programme that’s leading to the cells to divide uncontrollably, and we believe the BRAF mutation is driving that programme. The drug is normally blocking the genetics of the tumour, instead of trying to hinder the proliferation of the cells and, as a result, there are fewer unwanted effects, although there are a few. We are seeing some pretty dramatic and quick responses, and they are occurring in sites where we seldom see responses to chemotherapy, such as for example in the bone. Related StoriesCotellic accepted to be used in combination with vemurafenib for melanoma treatmentNew medication combination could be effective against malignant melanomaUCSF-led experts map out melanoma's genetic trajectories’There are some important caveats.